New Lupus Nephritis Treatments Are Cost Effective, ICER Determines

GSK's Benlysta and Aurinia's Lupkynis for lupus nephritis are priced in line with the drug pricing watch dog's health benefit price benchmark ranges.

A toy train pulling a cargo of money This picture could be a reference to 'money delivery', gravy train, cargo, freight. Also, money supply and transferring money or wiring money.
ICER says new lupus drug pricing is on track • Source: Shutterstock

The prices of GlaxoSmithKline plc's Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.'s Lupkynis (voclosporin) are in line with their anticipated clinical benefits for patients with lupus nephritis despite uncertainty about long-term use and outcomes, according to recommendations by the Institute for Clinical and Economic Review (ICER).

ICER – an independent organization that monitors the cost effectiveness of drugs in the US – released an evidence report...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category